Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Condition(s):Lymphoma, B-CellLast Updated:May 2, 2011Terminated
Hide Studies Not Open or Pending
Condition(s):Lymphoma, B-CellLast Updated:May 2, 2011Terminated
Condition(s):Diffuse Large B-cell Lymphoma (DLBCL)Last Updated:October 10, 2023Terminated
Condition(s):Non-Hodgkin’s LymphomaLast Updated:August 10, 2020Completed
Condition(s):LymphomaLast Updated:December 23, 2020Completed
Condition(s):DLBCL – Diffuse Large B Cell LymphomaLast Updated:March 12, 2024Recruiting
Condition(s):Diffuse Large B-cell Lymphoma (DLBCL)Last Updated:May 11, 2023Completed
Condition(s):Diffuse Large B Cell Lymphoma; Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell LymphomaLast Updated:December 9, 2020Not yet recruiting
Condition(s):Diffuse Large B Cell Lymphoma; Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell LymphomaLast Updated:October 11, 2023Active, not recruiting
Condition(s):Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma RefractoryLast Updated:October 30, 2023Recruiting
Condition(s):Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell LymphomaLast Updated:October 12, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.